Interleukin-4 (IL-4) is a Th2 cytokine that plays crucial roles in the immune response and has significant implications for neuroinflammation in neurodegenerative diseases. While primarily studied in the context of allergic responses and immune regulation, IL-4 has emerged as an important modulator of microglial activity and neuronal survival in Alzheimer's disease, Parkinson's disease, and other neurological conditions. title: IL-4 Protein
Interleukin-4 (IL-4) is a Th2 cytokine that plays crucial roles in the immune response and has significant implications for neuroinflammation in neurodegenerative diseases. While primarily studied in the context of allergic responses and immune regulation, IL-4 has emerged as an important modulator of microglial activity and neuronal survival in Alzheimer's disease, Parkinson's disease, and other neurological conditions. title: IL-4 Protein .infobox.infix-protein ; Protein Name : Interleukin-4 ; Gene Symbol : [IL4](/proteins/il4-protein) ; UniProt ID : [P05112](https://www.uniprot.org/uniprotkb/P05112) ; Molecular Weight : 15 kDa ; Subcellular Localization : Secreted ; Protein Family : IL-4/IL-13 family
Overview
IL-4 is a 129-amino acid Th2 cytokine that signals through the Type I receptor (IL-4Rα/γc) and Type II receptor (IL-4Rα/IL-13Rα1). It drives Th2 cell differentiation, promotes B cell class switching to IgE, and regulates macrophage polarization toward an anti-inflammatory (M2) phenotype. In the brain, IL-4 modulates microglial activity, influences synaptic plasticity, and affects neuronal function[@gordon2009].
The IL-4 signaling pathway involves:
JAK1/JAK3 activation following receptor engagement
In neurodegenerative diseases, shifting [microglia](/entities/microglia) toward an IL-4-polarized M2 state represents a therapeutic strategy to reduce chronic neuroinflammation[@colton2006].
Studies have shown that IL-4 can enhance microglial phagocytosis of amyloid-beta plaques while reducing the production of pro-inflammatory cytokines like TNF-α and IL-1β. This dual action makes IL-4 signaling an attractive therapeutic target for AD[@kiyota2012].
May enhance [alpha-synuclein](/mechanisms/alpha-synuclein) clearance
IL-4 has been shown to protect dopaminergic neurons from toxin-induced cell death in both in vitro and in vivo models of PD. The neuroprotective effects are mediated through activation of the PI3K/Akt pathway and upregulation of anti-apoptotic proteins[@chao2018].
Amyotrophic Lateral Sclerosis
Emerging evidence suggests IL-4 may play a role in ALS:
IL-4 and its signaling pathway are therapeutic targets:
IL-4 delivery: Direct IL-4 administration or gene therapy
IL-4 mimetics: Engineered IL-4 receptor agonists
Small molecule JAK inhibitors: Modulate downstream signaling
Cell-based therapy: IL-4-producing cells
Clinical Trials
While IL-4 therapy for neurodegeneration is still experimental:
IL-4 has been tested in autoimmune conditions
Gene therapy approaches are being explored
Recombinant IL-4 has favorable safety profile
Key Publications
[Gordon S, et al. (2009). Alternative activation of macrophages. Nat Rev Immunol](https://pubmed.ncbi.nlm.nih.gov/19158675/). PMID: 19158675(https://pubmed.ncbi.nlm.nih.gov/19158675/)
[Colton CA, et al. (2006). M1/M2 microglia in neurodegenerative disease. J Neurosci Res](https://pubmed.ncbi.nlm.nih.gov/16470720/). PMID: 16470720(https://pubmed.ncbi.nlm.nih.gov/16470720/)
[Kiyota T, et al. (2012). IL-4 gene therapy for Alzheimer's disease. Mol Ther](https://pubmed.ncbi.nlm.nih.gov/22215018/). PMID: 22215018(https://pubmed.ncbi.nlm.nih.gov/22215018/)
[Chao CC, et al. (2018). IL-4 protects dopaminergic neurons in Parkinson's disease. Exp Neurol](https://pubmed.ncbi.nlm.nih.gov/29395012/). PMID: 29395012(https://pubmed.ncbi.nlm.nih.gov/29395012/)
[渡邊 達也他 (2019). IL-4 and neuroinflammation in ALS. Neuroscience](https://pubmed.ncbi.nlm.nih.gov/30652345/). PMID: 30652345(https://pubmed.ncbi.nlm.nih.gov/30652345/)
The study of Il4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Gordon S, et al., (2009). Alternative activation of macrophages: mechanism and functions. Nat Rev Immunol (2009)](https://pubmed.ncbi.nlm.nih.gov/19158675/)
[Colton CA, et al., (2006). M1 and M2 microglia in neurodegenerative disease. J Neurosci Res (2006)](https://pubmed.ncbi.nlm.nih.gov/16470720/)
[Kiyota T, et al., (2012). IL-4 gene therapy for Alzheimer's disease. Mol Ther (2012)](https://pubmed.ncbi.nlm.nih.gov/22215018/)
[Chao CC, et al., (2018). IL-4 protects dopaminergic neurons in Parkinson's disease. Exp Neurol (2018)](https://pubmed.ncbi.nlm.nih.gov/29395012/)